Saturday, February 26, 2011

CEO Panel at Feb 17 BioPharma Symposium Featured in the Denver Business Journal

CEO Panel presenters at the Feb 17 BioPharma Symposium are featured in the current Denver Business Journal in an article by Technology Report Greg Avery. CEOs included: Steve Orndorff, Ariel Pharmaceuticals; Tim Rodell, GlobeImmune; and Robert Conway, Array BioPharma. This was the launch of the 2011 CBSA Symposium series, to be held quarterly.

Link to the article preview (full content requires a subscription)

Thursday, February 24, 2011

CBSA Feb FOCUS Spotlights Medtronic Navigation's New Education Center in Louisville, CO + Videos of BioPharma Symposium Keynote & Presenting CEOs

The CBSA's current newsletter spotlights Medtronic Navigation's New Education Center in Louisville, CO. - plus more....

Link to the publication pdf. Content includes:

Recap - CBSA's Holli Baumunk - pg 1
Medtronic Navigation Spotlight - pg 2
Biotech/Pharma Symposium - pg 3 **
CBSA Marketing Opportunities - pg 4
Investor Conference: Sept 2011 - pg 5
Upcoming CBSA Events Recap - pg 6

** Note: videos of the Keynote and CEO's participating in the Feb Symposium mentioned in the Focus newsletter are now available at the CBSA YouTube Channel:

Dr Fintan Steele, Colorado Initiative in Molecular Biotechnology, Keynote (five parts): http://www.youtube.com/watch?v=k9zBzOI5jig

Robert M. DiScipio, Aegis Analytical (two parts): http://www.youtube.com/watch?v=K0elthsxBIQ

CEO Panel - GlobeImmune, Ariel Pharmaceuticals & Array BioPharma (seven parts): http://www.youtube.com/watch?v=K0elthsxBIQ

Thursday, February 17, 2011

9News Interview: Bioscience Jobs & Today's Biopharma Symposium

CBSA President & CEO Holli Baumunk interviewed on 9News this morning with Gary Shapiro about job opportunities in Colorado's Bioscience Industry and shared details about today's Biotech & Pharma Symposium, 1-7 at the Denver Grand Hyatt.

There's still time to register for the Symposium: http://www.cobioscience.com/BookingRetrieve.aspx?ID=20284

Link to the 9News website - they're debuting a new website design today

Tuesday, February 15, 2011

2011 CBSA Symposium Series Launch: CEO Holli Baumunk Interviews on Business For Breakfast Today To Share Details

CBSA President & CEO Holli Baumunk interviewed on the Radio Colorado Network's Business for Breakfast broadcast this morning, about the association's upcoming launch of its 2011 Symposium Series. She interviewed with Business For Breakfast Co-Host Woody Vincent.

The CBSA's 2011 Symposium Series launches Thursday, February 17, with the session, "Biotech & Pharma," 1-7 p.m., at the Grand Hyatt Denver, 1750 Welton Street.

Advanced registration is required for the event at: http://www.cobioscience.com/BookingRetrieve.aspx?ID=20284. Cost: CBSA Members: $50, Non-Members: $100.

KRCN-AM 1060 is the flagship station of the Radio Colorado Network (RNC). RCN is the only full-time "Business Talk" radio station serving the greater Denver, Fort Collins, and Cheyenne WY communities. The network is also found on KVLE-AM 610 Vail/Aspen, KWYD AM 1580 Colorado Springs-Pueblo and KSKE 1450 Buena Vista, plus online at http://www.radioconetwork.com/radio/stream.html.

Link to listen to the Holli Baumunk interview (approximately 8 minutes)

You can subscribe to the Business For Breakfast podcast rss feed at: http://www.radioconetwork.com/rss/b4brss2.xml.

Monday, February 14, 2011

CBSA Launches 2011 Symposium Series With 'Biotech & Pharma' Session Feb 17 at Denver Grand Hyatt

The CBSA is launching its 2011 Symposium Series Thursday, February 17, with the session, "Biotech & Pharma," 1-7 p.m., at the Grand Hyatt Denver, 1750 Welton Street. The announcement is made by Holli Baumunk, CBSA President & CEO, who says "We're extremely fortunate to welcome four Colorado company CEOs as presenters at our first quarter Biotech & Pharma Symposium." Participating CEOs include: Robert M. Di Scipio, President and CEO, Aegis Analytical Corp.; Bob Conway, President and CEO, Array BioPharma; Tim Rodell, President and CEO, GlobeImmune; and Steve Orndorff, President and CEO, Ariel Pharmaceuticals. Other companies and organizations on the agenda include: the Colorado Initiative in Molecular Biotechnology, Pfizer, Amgen and Genentech.

"Information covered in Thursday's session will include: how health care reform will impact Colorado companies; how companies can prepare for health care reform, including biosimilars, Independent Payment Advisory Board, comparative effectiveness and tax increases; controlling costs and minimizing risks in the manufacturing and drug development process; and lessons Colorado companies have learned in the drug development process," Baumunk explains.

Link to the Business Wire release

Friday, February 11, 2011

"Democrats: Prove that incentives create jobs...Focus on results"

Quoting from the Feb 11 article by Ed Sealover:

"Bill proponents may point to a Feb. 2 report from the Colorado BioScience Association. In it, the CBSA stated that the state’s 3-year-old Bioscience Discovery Evaluation Grant Program, in which Colorado gives money to help bring university-created products to market, has created 598 jobs, resulting in $44 million in payroll.

Holli Baumunk, CBSA president and CEO, said her organization wrote the report because if it proved it leveraged the money well, the state might provide more funding.

She believes that other industries can and will produce such reports as the competition rises for tax expenditures.

'It’s just showing people that this is a great investment,' Baumunk said. 'And also, we want to make sure we show a good return on investment, because we’re going after further help.'

Link to the article at the Denver Business Journal website

Link to complete information about the Bioscience Discovery Evaluation Grant Program at the CBSA website

"Medical device makers oppose manufacturing tax"

Quoting from the Feb 11 article by Greg Avery:

"The CBSA has joined Washington, D.C.-based trade groups such as MDMA and AdvaMed in urging the state’s and other congressional delegations to repeal the tax, and to make other adjustments to the Affordable Care Act (ACA), though the industry supports many of its features.

Drug makers have particular concerns about one part of the ACA. The law creates a panel of presidential appointees with the power to alter reimbursement levels for drugs sold through Medicare and Medicaid, and the ability to appeal the panel’s decision isn’t defined, said Holli Baumunk, president and CEO of the CBSA.

Because of legislation in Congress to repeal or alter parts of the act, and a federal court fight over whether the government can require people to buy health insurance, there’s a lot of uncertainty clouding U.S. bioscience — and that undermines the country’s lead in the field, she said.

'People are trying to get a read on what will happen, and there’s just too many unknowns,' Baumunk said. 'Nationally, we see companies looking at developing [new products] in Europe and Asia first because they don’t know what’ll happen here.'"

Link to the Denver Business Journal article online

Thursday, February 03, 2011

Colorado is a Bio Friendly State: Video Recaps of the 2011 BioScience Day at the Colorado Capitol

Bioscience industry supporters gathered on the Colorado State Capitol campus yesterday to celebrate and review past legislative successes and look forward to Colorado's 2011 bioscience legislative initiatives. Here is a video recap of the event:

CBSA President Holli Baumunk at Colorado's 2011 BioScience Day at the Capitol - Baumunk Provides an Overview of the Bioscience Discovery Evaluation Grant Program's Return on Investment Figures and Previews the CBSA Legislative Initiatives for 2011.

http://www.youtube.com/watch?v=kCt-lP_MykU

Colorado Representative Jim Riesberg, CBSA 2011 Bill Sponsor


http://www.youtube.com/watch?v=NWj7fiHca9I

Colorado Speaker of the House Frank McNulty

http://www.youtube.com/watch?v=YRionuWrO8k

Colorado Senator Rollie Heath, CBSA 2011 Bill Sponsor


http://www.youtube.com/watch?v=dy43e2I77jA

Colorado Representative Cheri Gerou, CBSA 2011 Bill Sponsor


http://www.youtube.com/watch?v=NAC1X7HOYmY

Matthew Schumaker, Managing Director of Federal Government Relations at the Biotechnology Industry Organization - Q&A session


http://www.youtube.com/watch?v=bhNwsYiXYY8

Kevin Sweeney, Attorney, Life Sciences Group Chair, Polsinelli Shughart PC


http://www.youtube.com/watch?v=QEtVMJmO_QQ

'Colorado bioscience program creates 598 jobs'

Quoting from the Denver Post website:

"Colorado's Bioscience Discovery Evaluation Grant Program has created 598 jobs in the state, with payroll exceeding $44 million, according to the Colorado BioScience Association and the Colorado Office of Economic Development and International Trade.

Appropriated funding to date for the program has totaled $14 million; $10.8 million has been awarded as of August 2010, and $5.5 million has been appropriated for each of the next two years, said Holli Baumunk, the association's president and chief executive."

Link to denverpost.com

Colorado's Bioscience Discovery Evaluation Grant Program Creates 598 New Jobs in the State, with Payroll Exceeding $44 million

The Colorado BioScience Association (CBSA) and The Colorado Office of Economic Development and International Trade (OEDIT) have jointly released results of the Bioscience Discovery Evaluation Grant Program (BDEGP) at the CBSA's Third Annual "Bioscience Day at the Capitol" event. The announcement is made by Holli Baumunk, CBSA President & CEO, who says the BDEGP has more than met expectations since its inception in 2006, providing the state a significant return on investment.

Baumunk explains: "Appropriated funding to date for the BDEGP has totaled $14 million; $10.8 million has been awarded as of August 2010, and $5.5 million has been appropriated for each of the next two years. The program has created 598 direct and indirect jobs in the state, resulting in a payroll of more than $44 million. Another $68 million has been leveraged through follow-on investment, grants and matching funds, providing 8.3 times the state’s funding."

Link to the Business Wire release

Link to BDEGP Overview

Link to pdf of the complete report